Literature DB >> 28523157

Impact of maximum standardized uptake value of non-small cell lung cancer on detecting lymph node involvement in potential stereotactic body radiotherapy candidates.

Shanyuan Zhang1, Shaolei Li1, Yuquan Pei1, Miao Huang1, Fangliang Lu1, Qingfeng Zheng1, Nan Li2, Yue Yang1.   

Abstract

BACKGROUND: The retrospective study investigated the association between the maximum standardized uptake value (SUVmax) of primary tumor and lymph node involvement in potential stereotactic body radiotherapy (SBRT) candidates.
METHODS: A total of 185 patients with clinical stage I NSCLC were enrolled in the current study. All patients underwent lobectomy with systematic lymph node dissection following preoperative FDG-PET/CT scanning. The association between clinicopathological variables and lymph node involvement was analyzed by univariate and multivariate analysis. Spearman's correlation test was used to evaluate the correlation between them. Receiver operating characteristic (ROC) analysis was performed to calculate the area under the curve.
RESULTS: Among these patients, 22.1% had occult lymph node involvement, 15.1% were N1 and 7.0% were N2. Greater tumor size (P=0.007), elevated CEA (P=0.006), central location (P=0.002), higher SUVmax (P<0.001), solid nodule type (P=0.002), visceral pleural invasion (P=0.001) and presence of micropapillary and solid patterns (P=0.002) were significantly associated with lymph node involvement. In multivariate analysis, lymph node involvement was associated with central location (OR 5.784, 95% CI: 1.584-21.114, P=0.008), SUVmax (increase of 1 unite, OR 1.147, 95% CI: 1.035-1.272, P=0.009) and visceral pleural invasion (OR 3.044, 95% CI: 1.369-6.769, P=0.006). ROC area under the curve of SUVmax for lymph node involvement was 0.770 (95% CI: 0.698-0.841), the sensitivity and specificity were 85.4% and 63.2%, respectively. Spearman's correlation test showed that SUVmax of tumor mostly depended on tumor size and nodule type.
CONCLUSIONS: SUVmax of primary tumor was a predictor of lymph node involvement for potential SBRT candidates. Centrally located tumor and visceral pleural invasion were related to higher rate of nodal metastasis. Lobectomy and systemic lymph node dissection should be performed in these patients, instead of SBRT.

Entities:  

Keywords:  Potential SBRT candidates; SUVmax; lymph node involvement

Year:  2017        PMID: 28523157      PMCID: PMC5418246          DOI: 10.21037/jtd.2017.03.71

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  31 in total

1.  A comparison of surgical intervention and stereotactic body radiation therapy for stage I lung cancer in high-risk patients: a decision analysis.

Authors:  Varun Puri; Traves D Crabtree; Steven Kymes; Martin Gregory; Jennifer Bell; Jeffrey D Bradley; Clifford Robinson; G Alexander Patterson; Daniel Kreisel; Alexander S Krupnick; Bryan F Meyers
Journal:  J Thorac Cardiovasc Surg       Date:  2011-12-09       Impact factor: 5.209

2.  Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group.

Authors:  R J Ginsberg; L V Rubinstein
Journal:  Ann Thorac Surg       Date:  1995-09       Impact factor: 4.330

3.  Role of lymphatic invasion in the prognosis of patients with clinical node-negative and pathologic node-positive lung adenocarcinoma.

Authors:  Takahiro Mimae; Yasuhiro Tsutani; Yoshihiro Miyata; Tomoharu Yoshiya; Yuta Ibuki; Kei Kushitani; Yukio Takeshima; Haruhiko Nakayama; Sakae Okumura; Masahiro Yoshimura; Morihito Okada
Journal:  J Thorac Cardiovasc Surg       Date:  2013-12-31       Impact factor: 5.209

4.  Assessment of factors influencing FDG uptake in non-small cell lung cancer on PET/CT by investigating histological differences in expression of glucose transporters 1 and 3 and tumour size.

Authors:  Naohisa Suzawa; Morihiro Ito; Shanlou Qiao; Katsunori Uchida; Motoshi Takao; Tomomi Yamada; Kan Takeda; Shuichi Murashima
Journal:  Lung Cancer       Date:  2010-09-29       Impact factor: 5.705

5.  Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials.

Authors:  Joe Y Chang; Suresh Senan; Marinus A Paul; Reza J Mehran; Alexander V Louie; Peter Balter; Harry J M Groen; Stephen E McRae; Joachim Widder; Lei Feng; Ben E E M van den Borne; Mark F Munsell; Coen Hurkmans; Donald A Berry; Erik van Werkhoven; John J Kresl; Anne-Marie Dingemans; Omar Dawood; Cornelis J A Haasbeek; Larry S Carpenter; Katrien De Jaeger; Ritsuko Komaki; Ben J Slotman; Egbert F Smit; Jack A Roth
Journal:  Lancet Oncol       Date:  2015-05-13       Impact factor: 41.316

6.  Lobectomy, sublobar resection, and stereotactic ablative radiotherapy for early-stage non-small cell lung cancers in the elderly.

Authors:  Shervin M Shirvani; Jing Jiang; Joe Y Chang; James Welsh; Anna Likhacheva; Thomas A Buchholz; Stephen G Swisher; Benjamin D Smith
Journal:  JAMA Surg       Date:  2014-12       Impact factor: 14.766

7.  Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection.

Authors:  Robert J Downey; Timothy Akhurst; Mithat Gonen; Alain Vincent; Manjit S Bains; Steven Larson; Valerie Rusch
Journal:  J Clin Oncol       Date:  2004-08-15       Impact factor: 44.544

8.  Micropapillary and solid subtypes of invasive lung adenocarcinoma: clinical predictors of histopathology and outcome.

Authors:  Min Jae Cha; Ho Yun Lee; Kyung Soo Lee; Ji Yun Jeong; Joungho Han; Young Mog Shim; Hye Sun Hwang
Journal:  J Thorac Cardiovasc Surg       Date:  2013-11-04       Impact factor: 5.209

9.  Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography.

Authors:  Didier Lardinois; Walter Weder; Thomas F Hany; Ehab M Kamel; Stephan Korom; Burkhardt Seifert; Gustav K von Schulthess; Hans C Steinert
Journal:  N Engl J Med       Date:  2003-06-19       Impact factor: 91.245

10.  Factors predicting occult lymph node metastasis in completely resected lung adenocarcinoma of 3 cm or smaller.

Authors:  Jung-Jyh Hung; Yi-Chen Yeh; Wen-Juei Jeng; Yu-Chung Wu; Teh-Ying Chou; Wen-Hu Hsu
Journal:  Eur J Cardiothorac Surg       Date:  2016-01-27       Impact factor: 4.191

View more
  4 in total

1.  Comparison of prognostic values of primary tumor and nodal 18F-fluorodeoxyglucose uptake in non-small cell lung cancer with N1 disease.

Authors:  Chae Hong Lim; Seung Hyup Hyun; Seung Hwan Moon; Young Seok Cho; Joon Young Choi; Kyung-Han Lee
Journal:  Eur Radiol       Date:  2019-03-21       Impact factor: 5.315

2.  Pretreatment 18F-FDG Uptake Heterogeneity Predicts Treatment Outcome of First-Line Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer.

Authors:  Chengcheng Gong; Guang Ma; Xichun Hu; Yingjian Zhang; Zhonghua Wang; Jian Zhang; Yannan Zhao; Yi Li; Yizhao Xie; Zhongyi Yang; Biyun Wang
Journal:  Oncologist       Date:  2018-08-06

3.  Correlation of quantified metabolic activity in nonsmall cell lung cancer with tumor size and tumor pathological characteristics.

Authors:  Mehrdad Bakhshayesh Karam; Abtin Doroudinia; Bahareh Behzadi; Payam Mehrian; Abbas Yousefi Koma
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.889

4.  Temporal Heterogeneity of HER2 Expression and Spatial Heterogeneity of 18F-FDG Uptake Predicts Treatment Outcome of Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer.

Authors:  Chengcheng Gong; Cheng Liu; Zhonghua Tao; Jian Zhang; Leiping Wang; Jun Cao; Yannan Zhao; Yizhao Xie; Xichun Hu; Zhongyi Yang; Biyun Wang
Journal:  Cancers (Basel)       Date:  2022-08-17       Impact factor: 6.575

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.